Low-intensity extracorporeal shock wave therapy (LI-SWT) did not improve erectile dysfunction compared to a sham procedure in radical prostatectomy patients. Fewer than 20% of men in the LI-SWT group ...
High-risk localized and locally advanced prostate cancer patients treated with apalutamide - a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) - plus hormone therapy before and ...
The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved substantially over the past decade, with androgen receptor pathway inhibitors, taxanes, poly ...